Core D will provide logistical, regulatory, and research data management support for all clinical trial projects conducted under this grant application. It will maintain a comprehensive BMT repository database on all patients undergoing allogeneic HSCT, and ensure HIPAA compliant release of clinical outcomes data to researchers for correlation with their laboratory findings. The ultimate objective of this program project application is to understand the pathophysiology of chronic graft-vs.-host disease (GVHD) in humans. The focus of all projects is to develop targeted strategies that can prevent and control cGVHD. Core D will be responsible for the complete and accurate collection of individual patient data for all the clinical studies in this grant. Clinical data on patients collected through core D will be available to investigators in other cores so that they will have clinical correlates for their laboratory observations. Integrated data management is critical for all clinical projects and extend beyond patient care and clinical laboratory functions. Core D will coordinate the proper collection of detailed patient-level data in the BMT repository database, and assure that the highest quality data are available to achieve laboratory and clinical objectives. This core will interact extensively with staff from the Biostatistics Core C who can retrieve data directly from the BMT repository for correlative analyses. Core D will work closely with Core C to provide assistance in study design and analysis for the Projects. The purpose of the Data Management Core D is to provide the following services that will be utilized by all three Projects: 1. To help clinical and laboratory investigators identify the necessary patient-level information for their projects, and to design forms, procedures and databases to capture these data 2. To provide clinical data management for abstraction of individual patient information 3. To provide clinical trials with regulatory binder support and quality control for clinical data 4. To assure patient confidentiality and HIPAA compliance in the release of personal or clinical information from the HSCT repository to investigators who need this data for clinical correlation with their laboratory findings.

Public Health Relevance

All research projects in this application require coordinated clinical data in order to answer their respective scientific questions. It is the responsibility of Core D to provide complete support to the projects for these needs so that collection of patient information is timely, complete, of high quality, and immediately available for analysis.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dana-Farber Cancer Institute
United States
Zip Code
Cutler, Corey S; Koreth, John; Ritz, Jerome (2017) Mechanistic approaches for the prevention and treatment of chronic GVHD. Blood 129:22-29
Ho, Vincent T; Kim, Haesook T; Bavli, Natalie et al. (2017) Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT. Blood Adv 1:2269-2279
Gartlan, Kate H; Bommiasamy, Hemamalini; Paz, Katelyn et al. (2017) A critical role for donor-derived IL-22 in cutaneous chronic GVHD. Am J Transplant :
MacDonald, Kelli Pa; Blazar, Bruce R; Hill, Geoffrey R (2017) Cytokine mediators of chronic graft-versus-host disease. J Clin Invest 127:2452-2463
MacDonald, Kelli P A; Hill, Geoffrey R; Blazar, Bruce R (2017) Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. Blood 129:13-21
Wang, Kathy S; Kim, Haesook T; Nikiforow, Sarah et al. (2017) Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease. Blood 130:2889-2899
Asano, Takeru; Meguri, Yusuke; Yoshioka, Takanori et al. (2017) PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. Blood 129:2186-2197
Du, Jing; Paz, Katelyn; Flynn, Ryan et al. (2017) Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-? production. Blood 129:2570-2580
McKenna Jr, David H; Sumstad, Darin; Kadidlo, Diane M et al. (2017) Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials. Cytotherapy 19:250-262
Du, Jing; Paz, Katelyn; Thangavelu, Govindarajan et al. (2017) Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells. Blood 129:3121-3125

Showing the most recent 10 out of 186 publications